Skip to main content

At metaMe, we believe the best medicine may not be medicine at all. By developing innovative prescription digital therapeutics (PDTs) to combat many common chronic conditions, we’re putting the power to heal right in the hands of our patients.


Timothy Rudolphi

Tim has 30 years of pharmaceutical and healthcare experience with a diverse background in sales, global and US marketing, commercial operations, strategic planning, and business development. Most recently, Tim was Chief Business Officer at Aprecia Pharmaceuticals, the leader in 3-D printing of pharmaceutical drug products. Prior, Tim helped build Takeda Pharmaceuticals, starting with the company in 1999. He took on increasing roles of responsibility, including leading the US Sales & Managed Markets, Marketing, and BD teams. Tim has extensive experience bringing GI drugs to market including Amitiza, Prevacid, Dexilant, and Entyvio.

Danny Bernstein

Prior to founding metaMe, Dan founded the medication adherence company Medic8 Manager. Dan has training in architecture and experience in computer game design, including projects at Activision and Disney Interactive. Dan has been living with IBD-Crohn’s and IBS since his early teens.

Troy Hamilton

Troy Hamilton has more than 25 years of experience in the biopharmaceutical and healthcare industries. Currently, he is CEO of Ellodi Pharmaceuticals, a TPG Capital portfolio company. He has held several executive and global commercial leadership roles at Adare Pharmaceuticals, Synergy Pharmaceuticals, Shire Pharmaceuticals, and Johnson & Johnson’s Janssen Pharmaceuticals and McNeil Specialty Products. Troy has significant Gastroenterology-related experience in functional gastrointestinal disorders, inflammatory bowel disease, eosinophilic esophagitis, short bowel syndrome, rare pediatric cholestasis, and acid-peptic disorders. He also serves as a board member at Lazarus Pharmaceuticals and board advisor at New Perspectives, Inc. Troy received his Bachelor of Science and Doctorate degrees in Pharmacy from the University of the Sciences in Philadelphia and his MBA from St. Joseph’s University.

Ed Michael

Ed worked for 25 years at Abbott Laboratories where he served as Executive Vice President of Diagnostic Products. In this capacity, he oversaw $4B in revenues and 13,000 employees. Having formed many strategic alliances and research partnerships during his long career, Ed is closely connected with numerous leading companies and customers in the healthcare industry. From 2012 to 2013, he served on the Board of Directors at Cook County Hospitals System. Ed also currently serves on the Quidel Corporation Board of Directors and is a member of Chicago’s healthcare start-up community, MATTER. Ed holds a bachelor’s degree in politics and government and a juris doctorate from Indiana University in Bloomington.

Ken Greisman

Ken has 32 years of experience in biopharmaceutical and healthcare companies. For more than a decade, he was Senior Vice President, General Counsel, and Secretary at Takeda Pharmaceuticals U.S.A., Inc. Prior to joining Takeda, he was Vice President and Chief Legal Counsel at TAP Pharmaceutical Products, Inc. In those roles, he advised, guided, and sometimes led those companies on a broad range of highly significant matters. Prior to joining TAP, he worked as an attorney at Abbott Laboratories. Currently Ken is a venture capital and private equity investor. Ken earned a BA in economics from Northern Illinois University, a J.D. from Loyola University Chicago School of Law, and an MBA from the University of Chicago Booth School of Business.

Amy Gu, Board Observer

Amy has been recognized for her leadership in diversifying the male-dominated world of tech entrepreneurship and financing. Prior to her experience as an investor, she honed her innovation skills as an executive and adviser at a number of pioneering companies, including Evernote, Robinhood, and Udacity. Fast Company named Amy among its “Most Creative People of 2015,” Silicon Valley Business Journal listed her in their “40 under 40 of 2018,” and the National Venture Capital Association named her in their list of “Rising Stars in VC.” She holds an MBA from Stanford.